

Ira J. Goldberg, M.D.

CURRICULUM VITAE

Ira Jay Goldberg, M.D

Personal data

Date of Birth: March 11, 1949
Birthplace: Elizabeth, New Jersey
Citizenship: U.S.A.

Office: Department of Medicine, Division of Preventive Medicine and Nutrition
Columbia University College of Physicians & Surgeons
630 West 168th Street, PH10-305
New York, New York 10032
Phone: (212) 305-5961, FAX (212) 305-3231; Cell (917) 362-4592
Email: IJG3@columbia.edu

Home: 300 West 108th Street
Apt. 11A
New York, New York 10025
Phone: (212) 864-7594

Wife: Ina N. Cholst, M.D.
Children: Sarah Cholst Goldberg; birthday, June 9, 1986
Jacob Cholst Goldberg; birthday, June 9, 1986

Academic Training

College: Massachusetts Institute of Technology, B.S., 1971
Medical School: Harvard Medical School, M.D., 1975

Traineeship

Internship: New York University-Bellevue Hospital Medical Center
New York, NY, 1975-76

Residency: Jr. & Sr. Resident in Medicine
New York University-Bellevue Hospital Medical Center
New York, NY, 1976-78

Fellowship: Endocrinology & Metabolism, Mount Sinai School of Medicine
New York, NY, 1978-79. Supervisor - Dorothy T. Krieger

Fellowship: Arteriosclerosis and Metabolism, Mount Sinai School of Medicine
New York, NY, 1979-81. Supervisor - W. Virgil Brown

Board Certification

Internal Medicine - 1978
Endocrinology & Metabolism - 1981
New York State License: 127-401



Academic appointments

- 1981-1983 Instructor in Medicine
Mount Sinai School of Medicine
New York, NY
- 1983-1990 Assistant Professor of Medicine
Columbia University College of Physicians & Surgeons
New York, NY
- 1990-1996 Associate Professor of Medicine
Columbia University College of Physicians & Surgeons
New York, NY
- 1996- Professor of Medicine
Columbia University College of Physicians & Surgeons
- 2000- Chief, Division of Preventive Medicine and Nutrition
Columbia University College of Physicians & Surgeons
- 2005- Dickinson Richards Professor of Medicine
Columbia University

Hospital Appointments

- 1983 - 1990 Assistant Attending Physician, Department of Medicine
Columbia-Presbyterian Medical Center
- 1985 - 2000 Associate Director, Arteriosclerosis Research Center
Columbia-Presbyterian Medical Center
- 2000- Director, Center for Heart Disease Prevention
New York Presbyterian Medical Center
- 1990 - 1996 Associate Attending Physician, Department of Medicine
Columbia-Presbyterian Medical Center
- 1996 - Attending Physician, Department of Medicine
Columbia-University Medical Center
(New York Presbyterian Hospital)

Professional organizations and societies

- Association of American Physicians
- American Society for Clinical Investigation
- American Heart Association
- Fellow, Council on Arteriosclerosis
 - ATVB, leadership committee 06-
 - Advocacy Committee 06-
 - Nominating and membership committees 94-95
 - Abstract grading Committee 1995-
 - Nutrition Committee 1997-2000
 - Committee for Scientific Sessions Program 1997-2000, 2008-
 - Council on Nutrition, Physical Activity & Metabolism
 - Chair, Program Committee 2000-2001
- American Heart Association - New York City Affiliate
- Chairman, Committee on Cholesterol Education 1988-1990
 - Member - Community Programs 1988-1990
 - Professional Education Committee, 1988-1992



Ira J. Goldberg, M.D.

Peer review committee, 1993-1994. Co-chairman 1994-95, Chairman 95-97
Board of Directors (term 1993-1999)

American Heart Association, Heritage Affiliate
Board of Directors 1998-2005
Chair, Research Council 1998-00
Research Committee 2002-06

New York Diabetes Association
Chairman of the Clinical Society (1988-1989)
Symposium Committee, Chairman (1987)
Clinic Advisory Committee, Chairman (1985-1987)

American Federation for Clinical Research

American Diabetes Association
Abstract reviewer – 2000-2003
Session Chair – 2002,03

New York Lipid Club, President 1992-1993

Kern Aspen Bile/Lipid Conference, Board of Directors, 08-

Honors

Dr. Charles Kilo visiting Professor, Washington U, 2008
Robert Levy Memorial Lecturer, American Heart Association, 2007
MERIT Award – National Heart Lung and Blood Institute – 2000-2010.
Association of American Physicians – elected 1999
University Tenure, Columbia University, 1992
American Society for Clinical Investigation - elected 1991
Established Fellowship, New York Heart Association, 1988-1993
Clinician-Scientist Award, American Heart Association, 1981-1986
Session Chairman, American Heart Association Annual Scientific Sessions,
1988, 1990, 1991, 1993, 1995, 1996, 1997, 1998, 2000, 2001, 2002, 2004, 2006
University Senate, Columbia University 2001-2005

Invited speaker:

Gordon Conference on Lipoprotein Metabolism, 1992, speaker and session chair.
1996,1998, 2006

Gordon Conference on Atherosclerosis, 1995

Lofland Conference on Atherosclerosis, 1993

FASEB Conference on Chylomicron Metabolism, 1994

International Arteriosclerosis Society, 1994. Speaker and session chairman 1997

Visiting Professor, University of Rennes, Rennes, France, 1993.

Merck Frosst-McGill Lecturer in Lipid Metabolism, McGill University, 1993.

Baker Symposium on Cardiovascular Disease, Melbourne, Australia, 1997

Muenster Symposium on the Biology of the vessel wall. Muenster, Germany, 1998.

European Lipoprotein Club. Tutzing. German, 1999

Atherosclerosis, Thrombosis, Vascular Biology, spring meeting, 2000

Harrison lecture in diabetes (first invited speaker). U. Cal. Davis, 2000.

HDL and Cardiovascular Disease: Therapeutic Implications". Milan, Italy, 2000



International Diabetes Federation – Satellite on “Lipoproteins, vascular disease and macrovascular disease in diabetes”. Cancun, Mexico, 2000
Diabetic Dyslipidemia – American Diabetes Association annual meeting, 2001
43rd Annual Meeting, Biosciences of Lipids, Graz, Austria, 2002
James O Davis Distinguished Lecturer in cardiovascular science, U. Missouri, 2002
NIH Symposium – Metabolic imprinting and the long-term complications of diabetes – Development of atherosclerosis in diabetes, 2003
NIH Symposium – Alcohol and its complications – Clinical guidelines for alcohol usage, 2003
Israeli Atherosclerosis Society, Eilat, 2003, 2006, 2008 (Keynote speaker)
Olivecrona Symposium, University of Umea, Umea Sweden, 2003
ADA – New York Diabetes Scientific Meeting. From lipidologist back to diabetologist - 2003
Pharmacophore 2004, “Feeding the heart with fat” – Hyderabad, India
U of Toronto, Science of diabetes complications. 2004
U of Missouri – Cardiovascular Research Day 2004
Missouri Cardiovascular Metabolism Club, St. Louis, Lipid delivery, from blood to cardiomyocyte (Inaugural lecture) 2004
AHA Council on Basic Science, targeting heart failure, Keystone, CO, 2005, 2008
Berrie Diabetes Symposium, Jerusalem, Sept. 2005, New York, Nov, 2005
R Levine Diabetes Symposium, Los Angeles, 2005
Severence Hospital Diabetes Symposium, Seoul, 2006
International Society for Heart Research, Toronto, 2006, Cleveland, 2008
Cardiac Energy Metabolism in Heart Failure, Semiahmoo, WA, Sept, 2006
Botanicals and Cardiovascular Risk. Pennington Scientific Symposium, 2006, Baton Rouge.
Vascular Biology, Invited talks, Blood Vessel Club Session, Washington, DC 2007
6th Annual Metabolic Diseases Drug Discovery Summit (Keynote), San Diego, 2007
ATVB Council Annual Meeting, Plenary Talk, Triglycerides in the circulation, on the artery and in the heart. Atlanta, 2008
Lipotoxicity Meeting, U of Graz, Austria, 2008
Basic CV Science, AHA, Keystone, 2008
ACC/TCT Meeting, Washington DC, 2008
Visiting professor, U North Carolina, Chapel Hill, 2008
American Society for Nephrology, 2008
Richard Lewar Centre of Excellence in Cardiovascular Research, Distinguished Visiting Professor, University of Toronto, 2009

Recent University Hospital Rounds and Conferences

Medical Grand Rounds – Northwestern U, Albany Medical College, R Wood Johnson (NJ); SUNY Syracuse, NYU School of Medicine, U CA Davis; A Einstein College of Medicine, 2005, U Utah 2007, Washington U, 2008.
Cardiology rounds – U Illinois Chicago, NYU School of Medicine 2001; U Rochester, Yale University, U Pennsylvania, 2004; U Alabama, U Washington, 2005; Deborah Heart Center (NJ), Cardiology Grand Rounds, Hartford Hospital 2006, 2007, Columbia U, Whittaker CV Institute, Boston University 2007, Preventive Cardiology, Mayo Clinic, 2008, Tulane, 2008.



Endocrinology rounds – U South Carolina, Mt Sinai, 2002; UCLA, Yale University, 2002; Washington U (St Louis), SUNY Syracuse, Washington U, 2003; Yale University, A Einstein College of Medicine, Mt Sinai School of Medicine, NYU School of Medicine 2004; U of Arizona, U of Colorado, Ochsner Clinic, Beth Israel, NYC, U Washington, 2005, U of Arkansas, 2006; U of Utah, UCLA, St. Vincent's (NYC), U Cincinnati, Med College of Wisconsin, U Pittsburgh 2007, Mayo Clinic , Washington U, Baylor 2008,

Pathology rounds – Northwestern, 2005, Wake Forest, 2008

Physiology conference - U Texas Southwestern, Penn State 2007, SUNY Downstate, 2008

Departmental and university committees

Institutional Animal Care and Use Committee 1986-1994

Working Group of the curriculum revision committee - Preventive Medicine, Nutrition and the Social Context of Medicine 1991

Internship selection committee 1992-

Doctoral Committee, Institute of Human Nutrition, 1992-

Review committee – Department of Genetics, 1998-99

Young faculty mentoring committee – 1997-00

Columbia University Senate 2001-, External relations committee

Teaching experience and responsibilities

Director, Nutrition Section - 1st year medical school, 1992-1994

Preceptor, 3rd year clinical clerks in medicine. 1985-

Medical Service - Attending Physician, 1 month per year

Endocrinology Service - Attending Physician, 1 month per year

Arteriosclerosis Research Center - Associate director and attending physician, medical resident and endocrine fellow instruction in lipoprotein disorders

Abnormal Human Biology - preceptor, lipid - lipoprotein disorders

Nutritional Biochemistry, Institute of Human Nutrition, Lecturer on lipoprotein metabolism and atherosclerosis.

Overlook Hospital Lipid Clinic - (1987-1991)

Other professional activities

Medical Knowledge Self-Assessment Program of the American College of Physicians.

Endocrinology and Metabolism Subcommittee, 1994

Editorial: Reviewer for Journal of Clinical Investigation

Journal of Biological Chemistry

Journal of Lipid Research

American Journal of Physiology

Arteriosclerosis, Thrombosis, Vasc Biol

New England Journal of Medicine

Editorial board: Journal of Clinical Endocrinology & Metabolism 1997 – 01

Cardiology Reviews 1998-

Journal of Lipid Research – Associate Editor, 1999-

American Journal of Physiology: Endocrinology and Metabolism –2001-



Ira J. Goldberg, M.D.

Journal of Clinical Lipidology – Associate Editor, 2007-

Consultative:

Juvenile Diabetes Research Foundation complications review panel, 07-
NIH – NIDDK - SEP ZRG1 EMNR B02(diabetes complications) Chairman, 08
SEP (exercise, insulin action, and muscle metabolism); Chairman, 07
SEP (EMNR;energy metabolism, nutrition and reproductive science, Chairman.
NIH – PPG reviewer NHLBI
NIH – DIDDk-B- subcommittee study section. (fellowship grant reviews) 06
NIH – Mouse metabolic phenotyping centers, review. Chair. 06
NIH – Data safety monitoring board, Atherosclerosis/Vascular Disease SCCORs 06-
NIH - Metabolism Study Section - Ad hoc reviewer, 1992-93,96,97,99,00,01;
Reviewer 02-04. Chairman - 2004
NIH – Study section on cellular aspects of diabetes and obesity (CADO). Member.
Term 2004, Chair 2004-06
Diabetic cardiomyopathy RFA review 2000, Special Emphasis – Lipids/Nutrition 2000
New York Diabetes Association, 1986-1989
American Heart Association, New York City Affiliate Peer review committee, 1993-
1997. Chair 1996-97.
AHA, Northeast regional consortium, 1998-99
American Heart Association, New York State Affiliate, 1990.
NHLBI- Special Review Committee for Clinical Investigator and Physician Scientist
Awards, 1987, 1992, 1994.
Veteran's Administration Health Services and Research Administration, 1997

Current Grant Support:

NHLBI. R37-HL45095 NIH-MERIT Award: PI. IJ Goldberg. 04/1/95-3/31/10, 4/01/000-
Extracellular regulation of lipoprotein lipase activity.
This project focuses on production of LpL transgenic mice and the use of those
mice to study lipid uptake into tissues. Specifically the roles of endothelial
versus myocyte surface LpL will be assessed
NHLBI. R01-HL073029. PI. IJ Goldberg. 04/01/03-03/31/08.
Mechanisms of fatty acid uptake by cardiac muscle.
Studies of the roles of fatty acid loss due to heart LpL deficiency and excess on
lipid uptake and cardiac gene expression.
NHLBI. P01-HL54591. AR Tall, P.I., Goldberg,I, RI: Project 4. 07/01/05-06/30/10.
Hyperglycemia, aldose reductase and murine atherosclerosis.
To study the effects of macrophage and endothelial aldose reductase expression
on atherosclerosis.
NHLBI. P50HL077113. PI. D. Kelly, Washington University SCCOR in cardiac
dysfunction and disease. Consortium- collaborator. 12/01/04-11/30/09.
Project 1 – Altered PPAR α signaling in the ischemic diabetic heart.
This grant includes specific experiments to determine how changes in cardiac
LpL expression alter heart function in several models created at Washington



Ira J. Goldberg, M.D.

University.

NHLBI. U01-HL087945. Goldberg, Ira J., PI. 09/01/06-08/31/11

Creating Glucose Responsive Cardiovascular Complications in the mouse.

This grant shared with Dr. E. Fisher (NYU) is part of an NIH consortium to develop models of diabetic atherosclerosis.

Postdoctoral training grants: Arteriosclerosis. P.I. IJ Goldberg, renewed 2008.

Nutrition. PI R.J. Deckelbaum, M.D. Participating Investigator:

American Diabetes Association- Mentor-Based Postdoctoral Fellowship Research

Award. 06/01/2003 – 06/30/2010

Takeda ADA Cardiovascular complications postdoctoral award. 2007-2009.



Original, peer-reviewed articles

1. **Goldberg IJ**, LK Brown, and EJ Rayfield. Disopyramide (Norpace)- induced hypoglycemia. Am J Med 69:463-466, 1980.
2. **Goldberg IJ**, NA Le, JR Paterniti, HN Ginsberg, FT Lindgren and WV Brown. Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. J Clin Invest 70:1184-1192, 1982.
3. **Goldberg IJ**, NA Le, HN Ginsberg, JR Paterniti and WV Brown. Metabolism of apoprotein B in cynomolgus monkey: evidence for independent production of low-density lipoprotein apoprotein B. Am J Physiol 244:E196-E201, 1983.
4. Soybel D, J Jaspan, K Polonsky, **IJ Goldberg**, E Rayfield and H Tager. Differential Immunoreactivity of plasma glucagon components in man: Studies with different glucagon antibodies. J Clin Endo Metab 56:612-618, 1983.
5. Ginsberg H, **IJ Goldberg**, P Wang-Iverson, E Gitler, NA Le, HS Gilbert and WV Brown. Increased catabolism of native and cyclohexanedione-modified low density lipoprotein in subjects with myeloproliferative diseases. Arteriosclerosis 3:233-241, 1983.
6. Rayfield EJ, **IJ Goldberg**, HA Mitty and A Aufses Jr. Transportal blood sampling for preoperative localization of insulinomas. Mt Sinai J Med. 50:258-262, 1983.
7. **Goldberg IJ**, JR Paterniti and WV Brown. Measurement of lipoprotein lipase and hepatic triacylglycerol lipase in post-heparin plasma of the cynomolgus monkey. Biochim Biophys Acta 752:172-177, 1983.
8. **Goldberg IJ**, JR Paterniti, B Franklin, HN Ginsberg, F Ginsberg-Fellner and WV Brown. Transient lipoprotein lipase deficiency with hyperchylomicronemia. Am J Med Sci 286:28-31, 1983.
9. Gibson JC, A Rubinstein, N Ngai, HN Ginsberg, NA Le, RE Gordon, **IJ Goldberg** and WV Brown. Immunoaffinity isolation of apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 835:113-123, 1985.
10. **Goldberg IJ**, RG Mazlen, A Rubinstein, JC Gibson, JR Paterniti, Jr., FT Lindgren and WV Brown. Plasma lipoprotein abnormalities associated with acquired hepatic triglyceride lipase deficiency. Metabolism 34:832-835, 1985.
11. **Goldberg IJ**, WS Blaner and DS Goodman. Immunologic and enzymatic Comparisons between human and bovine lipoprotein lipase. Arch Biochem Biophys 244:580-584, 1986.
12. **Goldberg IJ**, RS Rosenfeld, I Paul and B Leeman. Generation of plasma free cholesterol from circulating lipoprotein-associated cholestryl ester. Am J Physiol 250:E265-E268, 1986.
13. **Goldberg IJ**, JR Paterniti, DS France, G Martinelli and JA Cornicelli. Production and use of an inhibitory monoclonal antibody to human lipoprotein lipase. Biochim Biophys Acta 878:168-176, 1986.
14. Ginsberg HN, NA Le, **IJ Goldberg**, JC Gibson, A Rubinstein, P Wang-Iverson, R Norum and WV Brown. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78:1287-1295, 1986.
15. The Lovastatin Study Group II. Therapeutic response to lovastatin (Mevinolin) in nonfamilial hypercholesterolemia: A multicenter study. J Am Med Assoc 256:2829-2834, 1986.
16. **Goldberg IJ**, NA Le, B Leeman, WV Brown and FT Lindgren. Evidence for heterogeneity of low-density lipoprotein metabolism in the cynomolgus monkey. Biochim Biophys Acta 879:179-185, 1986.
17. **Goldberg IJ**, JJ Kandel, CB Blum and HN Ginsberg. Association of plasma lipoproteins



- with postheparin lipase activities. *J Clin Invest* 78:1523-1528, 1986.
- 18. **Goldberg IJ**, NA Le, HN Ginsberg, RM Krauss and FT Lindgren. Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey. *J Clin Invest* 81:561-568, 1988.
 - 19. **Goldberg IJ**, DA Handley, TM Vanni, JR Paterniti Jr. and JA Cornicelli. Membrane-bound lipoprotein lipase on human monocyte-derived macrophages: localization by immunocolloidal gold technique. *Biochim Biophys Acta* 959:220-228, 1988.
 - 20. Eckel RH, **IJ Goldberg**, L Steiner, TJ Yost and JR Paterniti Jr. Plasma lipolytic activity. relationship to postheparin lipolytic activity and evidence for metabolic regulation. *diabetes* 37:610-615, 1988.
 - 21. Saxena U, L Witte and **IJ Goldberg**. Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acids. *J Biol Chem* 264:4349-4355, 1989
 - 22. **Goldberg IJ**, DR Soprano, ML Wyatt, TM Vanni, TG Kirchgessner and MC Schotz. Localization of lipoprotein lipase mRNA in rat tissues. *J Lipid Res* 30:1569-1577, 1989.
 - 23. Traber MG, **IJ Goldberg**, E Davidson, N Lagmay and HJ Kayden. Vitamin E uptake by human intestinal cells during lipolysis in vitro. *Gastro* 98:96-103, 1990.
 - 24. Kern PA, RA Martin, J Carty, **IJ Goldberg** and JM Ong. Identification of lipoprotein lipase immunoreactive protein in pre- and postheparin plasma from normal subjects and patients with type 1 hyperlipoproteinemia. *J Lipid Res* 31:17-26, 1990.
 - 25. Saxena U and **IJ Goldberg**. Interaction of lipoprotein lipase with glycosaminoglycans and apolipoprotein CII; Effects of free-fatty-acids. *Biochim Biophys A*. 1043:161-168, 1990.
 - 26. **Goldberg IJ**, CA Scherardi, LK Yacoub, U Saxena and CL Bisgaier. Lipoprotein apoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. *J Biol Chem* 265:4266-4272, 1990.
 - 27. Gemson DH, RP Sloan, P Messeri and **IJ Goldberg**. A public health model for cardiovascular risk reduction: Impact of cholesterol screening with brief non-physician counseling. *Arch Int Med* 150:985-989, 1990.
 - 28. Saxena U, L Witte and **IJ Goldberg**. Tumor necrosis factor induced release of endothelial cell lipoprotein lipase. *Arteriosclerosis* 10:470-476, 1990.
 - 29. **Goldberg IJ**, WS Blaner, TM Vanni, M Moukides and R Ramakrishnan. Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism: Studies in normal and lipoprotein lipase-inhibited monkeys. *J Clin Invest* 86: 463-473, 1990.
 - 30. **Goldberg IJ**, RS Rosenfeld, I Paul, LK Miller and ML Tiell. Rapid transformation of [³H]cholesteryl ester in rat high-density lipoprotein: in vivo and in vitro studies. *Steroids* 55:308-313, 1990.
 - 31. Saxena U, MG Klein and **IJ Goldberg**. Metabolism of endothelial cell-bound lipoprotein lipase: Evidence for heparan sulfate proteoglycan-mediated internalization and recycling. *J Biol Chem* 265:12880-12886, 1990.
 - 32. **Goldberg IJ**, S Holleran, R Ramakrishnan, M Adams, RH Palmer, RB Dell and DS Goodman. Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. *J Clin Invest* 86:801-808, 1990.
 - 33. Yacoub Y, TM Vanni and **IJ Goldberg**. Lipoprotein lipase mRNA in neonatal and adult mouse tissues: comparison of normal and combined lipase deficiency (cld) mice assessed by in situ hybridization. *J Lipid Res* 31:1845-1852, 1990.
 - 34. Saxena U, MG Klein and **IJ Goldberg**. Transport of lipoprotein lipase across endothelial cells. *Proc Natl Acad Sci USA* 88:2254-2258, 1991.
 - 35. Jiang XC, P Moulin, EM Quinet, **IJ Goldberg**, LK Yacoub, LB Agellon, D Compton, R Schnitzer-Polokoff and AR Tall. Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. *J Biol Chem* 266:4631-4639, 1991.
 - 36. Saxena U, MG Klein and **IJ Goldberg**. Identification and characterization of the endothelial



- cell surface lipoprotein lipase receptor. *J Biol Chem* 266: 17516-17521, 1991.
37. Fried SK, IJ Turkenkopf, **IJ Goldberg**, MH Doolittle, TG Kirchgessner, MC Schotz, PR Johnson and MRC Greenwood. Mechanisms of increased lipoprotein lipase in fat cells of obese Zucker rats. *A J Physio* 261:E653-E660, 1991.
38. Yla-Herttuala S, BA Lipton, ME Rosenfeld, **IJ Goldberg**, D Steinberg and JL Witztum. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. *Proc Natl Acad Sci USA* 88:10143-10147, 1991.
39. Saxena U, MG Klein, TM Vanni and **IJ Goldberg**. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. *J Clin Invest* 89:373-380, 1992.
40. Ishimura-Oka K, CF Semenkovich, F Faustinella, **IJ Goldberg**, NS Shachter, LC Smith, T Coleman, WA Hide, WV Brown, K Oka and L Chan. A missense ($\text{Asp}^{250} \rightarrow \text{Asn}$) mutation in the lipoprotein lipase gene in two unrelated families with familial lipoprotein lipase deficiency. *J Lipid Res* 33:745-754, 1992.
41. Sprecher DL, J Kobayashi, M Rymaszewski, **IJ Goldberg**, BV Harris, PS Bellet, D Ameis, RL Yunker, DM Black, EA Stein, MC Schotz and DA Wiginton. $\text{Trp}^{64} \rightarrow \text{nonsense}$ mutation in the lipoprotein lipase gene. *J Lipid Res* 33:859-866, 1992.
42. Sasaki A and **IJ Goldberg**. Lipoprotein lipase release from BFC-1 β adipocytes: Effects of triglyceride-rich lipoproteins and lipolysis products. *J Biol Chem* 267:15198-15204, 1992.
43. Sivaram P, MG Klein and **IJ Goldberg**. Identification of a heparin-releasable lipoprotein lipase binding protein from endothelial cells. *J Biol Chem* 267:16517-16522, 1992.
44. Rumsey SC, JC Obunike, Y Arad, RJ Deckelbaum and **IJ Goldberg**. Lipoprotein lipase - mediated uptake and degradation of low density lipoproteins by fibroblasts and macrophages. *J Clin Invest* 90:1504-1512, 1992.
45. **Goldberg IJ**, TM Vanni and R Ramakrishnan. Effects of Intralipid-induced hypertriglyceridemia on plasma high-density lipoprotein metabolism in the cynomolgus monkey. *Metabolism* 41:1176-1184, 1992.
46. Stins MF, FR Maxfield and **IJ Goldberg**. Polarized binding of lipoprotein lipase to endothelial cells: Implications for its physiological actions. *Arterioscler Thromb* 12:1437-1446, 1992.
47. Seres DS, GW Strein, SA Hashim, **IJ Goldberg** and NW Levin. Improvement of lipoprotein profiles during high-flux dialysis. *J Am Soc Nephrology* 3:1409-1415, 1993.
48. Horowitz BS, **IJ Goldberg**, J Merab, TM Vanni, R Ramakrishnan and HN Ginsberg. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. *J Clin Invest* 91:1743-1752, 1993.
49. Lovastatin study groups I through IV. Lovastatin 5-year safety and efficacy study. *Arch Intern Med* 153:1079-1087, 1993.
50. Edwards JJ, **IJ Goldberg**, JS Parks, H Xu and WD Wagner. Lipoprotein lipase enhances the interaction of low density lipoproteins with artery-derived extracellular matrix proteoglycans. *J Lipid Res* 34:1155-1163, 1993.
51. Tornoci L, CA Scheraldi, X Li, H Ida, **IJ Goldberg** and N-A Le. Abnormal activation of lipoprotein lipase by non-equilibrating apo C-II: Further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. *J Lipid Res* 34:1793-1803, 1993.
52. Stins MF, P Sivaram, A Sasaki and **IJ Goldberg**. Specificity of lipoprotein lipase binding to endothelial cells. *J Lipid Res* 34:1853-1861, 1993.
53. Sivaram P, S Wadhwani, MG Klein, A Sasaki and **IJ Goldberg**. Biotinylation of lipoprotein lipase and hepatic triglyceride lipase: Application in the assessment of cell binding sites. *Analytic Biochem* 214:511-516, 1993.



54. Sasaki A, P Sivaram and **IJ Goldberg**. Lipoprotein lipase binding to adipocytes: evidence for the presence of a heparin-sensitive binding protein. *A J Physio* 265: E880-E888, 1993.
55. Shachter NS, T Hayek, T Leff, JD Smith, DW Rosenberg, A Walsh, R Ramakrishnan, **IJ Goldberg**, HN Ginsberg and JL Breslow. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. *J Clin Invest* 93:1683-1690, 1994.
56. Sivaram P, SY Choi, LK Curtiss and **IJ Goldberg**. An amino-terminal fragment of apolipoprotein B binds to lipoprotein lipase and may facilitate its binding to endothelial cells. *J Biol Chem* 269:9409-9412, 1994.
57. Obunike JC, IJ Edwards, SC Rumsey, L Curtiss, WD Wagner, RD Deckelbaum and **IJ Goldberg**. Cellular differences in lipoprotein lipase-mediated uptake of low density lipoproteins. *J Biol Chem* 269:13129-13135, 1994.
58. Rutledge JC and **IJ Goldberg**. Lipoprotein lipase (LpL) affects low density lipoprotein (LDL) flux through vascular tissue: Evidence that LpL increases LDL accumulation in vascular tissue. *J Lipid Res* 35: 1152-1160, 1994.
59. Blaner WS, JC Obunike, SB Kurlandsky, M Al-Haideri, R Piantedosi, RJ Deckelbaum and **IJ Goldberg**. Lipoprotein lipase hydrolysis of retinyl ester: Possible implications for retinoid uptake by cells. *J Biol Chem* 269:16559-16565, 1994.
60. Parthasarathy N, **IJ Goldberg**, P Sivaram, B Mulloy, DM Flory and WD Wagner. Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase. *J Biol Chem* 269:22391-22396, 1994.
61. Zhong S, **IJ Goldberg**, C Bruce, E Rubin, J Breslow and A Tall. Human apoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesterol ester transfer protein in transgenic mice. *J Clin Invest* 94:2457-2467, 1994.
62. Choi SY, P Sivaram, DE Walker, LK Curtiss, D Gretchen, S Sturley, A Attie, RJ Deckelbaum and **IJ Goldberg**. Lipoprotein lipase association with lipoproteins involves protein-protein interaction with apolipoprotein B. *J Biol Chem* 270:8081-8086, 1995.
63. Edwards IJ, H Xu, JC Obunike, **IJ Goldberg** and WD Wagner. Differentiated macrophages synthesize a heparan sulfate proteoglycan and an oversulfated chondroitin sulfate proteoglycan that bind lipoprotein lipase. *Arterioscler Thromb Vasc Biol* 15:400-409. 1995.
64. Sivaram P, JC Obunike and **IJ Goldberg**. Lysolecithin induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix. *J Biol Chem* 270:29760-29765, 1995.
65. Parthasarathy N, **IJ Goldberg**, P Sivaram and WD Wagner. Isolation of heparin-derived oligosaccharides containing 2-O-sulfated hexuronic acids, by lipoprotein lipase affinity chromatography. *J Biochem Biophys* 32:27-32, 1996.
66. Sivaram P, T Vanni-Reyes and **IJ Goldberg**. Endothelial cells synthesize and process apolipoprotein B. *J Biol Chem* 271:15261-15266, 1996.
67. Pang L, P Sivaram and **IJ Goldberg**. Cell surface expression of an amino-terminal Fragment of apolipoprotein B increases lipoprotein lipase binding to cells. *J Biol Chem* 271:19518-19523, 1996
68. Obunike JC, P Sivaram, L Paka, MG Low and **IJ Goldberg**. Lipoprotein lipase degradation by adipocytes: Receptor-associated protein (RAP) sensitive and proteoglycan mediated pathways. *J Lipid Res* 37:2439-2449, 1996
69. Masucci-Margolis L, **IJ Goldberg**, C Bisgaier, H Serajuddin, OL Francone, JL Breslow and AR Tall. A mouse model with features of familial combined hyperlipidemia. *Science* 275:391-397, 1997
70. Choi SY, L Pang, PA Kern, HJ Kayden, LK Curtiss, T Vanni-Reyes and **IJ Goldberg**. Dissociation of LPL and LDL: effects of lipoproteins and anti-apoB antibodies. *J Lipid*



Res 38:77-85, 1997

71. Hussein MM, **IJ Goldberg**, KH Weisgraber, RW Mahley and TL Innerarity. Uptake of chylomicrons by the liver, but not by the bone marrow, is modulated by lipoprotein lipase activity. Arterio Thromb Vasc Biol 17:1407-1413, 1997.
72. Obunike JC, S Paka, P Sivaram and **IJ Goldberg**. Lipoprotein lipase can function as a monocyte adhesion protein. Arterio Thromb Vasc Biol 17:1414-1420, 1997
73. Rutledge JC, MW Woo, AA Rezai, LK Curtiss and **IJ Goldberg**. Lipoprotein lipase increases lipoprotein binding to the artery wall and increases endothelial layer permeability by formation of lipolysis products. Circ Res 80:819-828, 1997.
74. Pillarisetti S, S Paka, A Sasaki, T Vanni-Reyes, B Yin, N Parthasarathy, W D Wagner and **I J Goldberg**. Endothelial cell heparanase modulation of lipoprotein lipase activity: Evidence that heparan sulfate oligosaccharide is an extracellular chaperone. J Biol Chem 272:15753-15759, 1997
75. Yin B, JD Loike, Y Kako, PH Weinstock, JL Breslow, SC Silverstein and **IJ Goldberg**. Lipoprotein lipase regulates Fc receptor-mediated phagocytosis by macrophages maintained in glucose-deficient medium. J Clin Invest 100:649-657, 1997
76. Pillarisetti S, L Paka, JC Obunike, L Berglund and **IJ Goldberg**. Subendothelial retention of lipoprotein (a): Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 100:867-874, 1997
77. Al-Hadairi M, **IJ Goldberg**, NF Galeano, A Gleeson, ET Vogel, M Gorecki, SL Sturley and RJ Deckelbaum. Heparan sulfate proteoglycan-mediated uptake of apolipoproteinE-triglyceride-rich lipoprotein particles: A major pathway at physiological particle concentrations. Biochemistry 36:12766-12772, 1997
78. Voyziakis E, **IJ Goldberg**, AS Plump, EM Rubin, JL Breslow and LS Huang. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res 39:313-321, 1998
79. Nielsen LB, M Veniant, J Boren, M Raabe, JS Wong, C Tam, L Flynn, T Vanni-Reyes, MD Gunn, **IJ Goldberg**, RL Hamilton and SG Young. Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: Evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circ 98:13-16, 1998
80. Choi, SC, **IJ Goldberg**, LK Curtiss and AD Cooper. Interaction between apoB and hepatic lipase mediates the uptake of apoB-containing lipoproteins. J Biol Chem 273:20456-20462, 1998
81. Merkel M, PH Weinstock, T Chajek-Shaul, H Radner, B Yin, JL Breslow and **IJ Goldberg**. Lipoprotein lipase expression exclusively in liver: A mouse model for metabolism in the neonatal period and during cachexia. J Clin Invest 102:893-901, 1998
82. Merkel M, YS Kako, H Radner, IS Cho, R Ramasamy, JD Brunzell, **IJ Goldberg** and JL Breslow. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: Direct evidence that lipoprotein lipase bridging occurs *in vivo*. Proc Natl Acad Sci USA 95:13841-13846, 1998.
83. **Goldberg IJ**, WD Wagner, L Pang, L Paka, LK Curtiss, JA DeLozier GA Shelness, CSH Young and S Pillarisetti. The NH₂-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminoglycans. J Biol Chem 273:35355-35361, 1998
84. Van Bennekum AM, Y Kako, PH Weinstock, EH Harrison, RJ Deckelbaum, **IJ Goldberg** and WS Blaner. Lipoprotein lipase expression level influences tissue clearance of chylomicron retinyl ester. J Lipid Res 40:565-574, 1999.
85. Balagopalakrishna C, L Paka, S Pillarisetti and **IJ Goldberg**. Lipolysis-induced-iron release from diferric transferrin: possible role of lipoprotein lipase in LDL oxidation. J. Lipid Res 40:1347-1356, 1999.



86. Nielsen LB, M Sullivan, T Vanni-Reyes, **IJ Goldberg** and SG Young. The DNA sequences required for apolipoprotein B expression in the heart are distinct from those required for expression in the intestine. *J Mol Cell Cardiol* 4:695-703, 1999.
87. Kako Y, L-S Huang, J Yang, T Katopodis, R Ramakrishnan and **IJ Goldberg**. Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice: Effects on lipoproteins and atherosclerosis. *J Lipid Res*, 40:2185-2194, 1999.
88. Paka L, **IJ Goldberg**, JC Obunike, SY Choi, U Saxena, ID Goldberg, S Pillarisetti. Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth? *J Biol Chem*, 274:36403-36408, 1999.
89. Obunike JC, S Pillarisetti, L Paka, Y Kako, MJ Butteri, Y-Y Ho, WD Wagner, N Yamada, T Mazzone, RJ Deckelbaum, and **IJ Goldberg**. The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production. *Arterio Thromb Vasc Biol* 20:111-118, 2000
90. **Goldberg IJ**, T Vanni-Reyes, S. Ramakrishnan, S Holleran, and HN Ginsberg. Circulating lipoprotein profiles are modulated differently by lipoprotein lipase in obese humans. *J Cardiovascular Risk*, 7: 41-47, 2000
91. Rutledge JC, AE Mullick, G Gardner, and **IJ Goldberg**. Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: Roles of VLDL and HDL. *Circ Res* 86:768-773, 2000
92. Ebara T, Conde K, Y Kako, Y Liu, Y Xu, R. Ramakrishnan, **IJ Goldberg**, and NS Shachter. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. *J Clin Invest*, 105: 1807-1818, 2000
93. Hussain MM, JC Obunike, A Shaheen, MJ Hussain, GS Shelness, and **IJ Goldberg**. High affinity binding between lipoprotein lipase and lipoproteins involves multiple ionic and hydrophobic interactions, does not require enzyme activity, and is modulated by glycosaminoglycans. *J Biol Chem* 275:29324-29330, 2000
94. Seo T, M Al-Haideri, E Treskova, TS Worgall, Y Kako, **IJ Goldberg**, and RJ Deckelbaum. Lipoprotein lipase-mediated selective uptake from low density lipoprotein requires cell surface proteoglycans and is independent of scavenger receptor class B type 1 (SR-BI). *J Biol Chem* 275: 30355-30362, 2000
95. Parthasarathy N, LF Gotow, JD Bottoms, JC Obunike, A Naggi, B Casu, **IJ Goldberg**, and WD Wagner. Influence of glucose on production and N-sulfation of heparan sulfate in cultured adipocyte cells. *Molecular Cellular Biochem* 213:1-9, 2000
96. Li Z, Y Kako, L Pang, MW Freeman, JM Glick, X Wang and **IJ Goldberg**. Effects of overexpression of the amino-terminal fragment of apolipoprotein B on apolipoprotein B and lipoprotein production. *J Lipid Res* 41:1912-1920, 2000
97. Schönherr E, B Zhao, H Haussler, M Müller M, C Langer, WD Wagner, **IJ Goldberg**, and H Kresse. Lipoprotein lipase-mediated interactions of small proteoglycans and low density lipoproteins. *Eur J Cell Biol* 79:689-696, 2000
98. Obunike JC, EP Lutz, Z Li, L Paka, T Katopodis, DK Strickland, KF Kozarsky, S Pillarisetti and **IJ Goldberg**. Transcytosis of lipoprotein lipase across cultured endothelial cells requires both heparan sulfate proteoglycans and the very low density lipoprotein receptor. *J Biol Chem* 276:8934-8941, 2001.
99. Lutz EP, M Merkel, Y Kako, K Melford, H Radner, JL Breslow, A Bensadoun and **IJ Goldberg**. Heparin-binding defective lipoprotein lipase is unstable and causes abnormalities in lipid delivery to tissues. *J Clin Invest* 107:1183-1192, 2001.
100. Kim JK, JJ Fillmore, Y Chen, C Yu, IK Moore, M G Pypaert, EP Lutz, Y Kako, W Velez-Carrasco, **IJ Goldberg**, JL Breslow and GI Shulman. Tissue-specific overexpression of lipoprotein lipase causes tissue specific insulin resistance. *Proc Natl Acad Sci USA* 98:7522-7527, 2001.



101. Merkel M, J Heeren, W Dudeck, F Rinninger, H Radner, JL Breslow, **IJ Goldberg**, R Zechner, and H Greten Inactive Lipoprotein Lipase (LPL) Alone Increases Selective Cholesterol Ester Uptake in Vivo, Whereas in the Presence of Active LPL It Also Increases Triglyceride Hydrolysis and Whole Particle Lipoprotein Uptake. *J Biol Chem* 277:7405-7411, 2002.
102. Yagyu H, EP Lutz, Y Kako, S Marks, Y Hu, SY Choi, A Bensadoun, and **IJ Goldberg**. VLDL receptor deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency. *J Biol Chem*. 277:10037-10043, 2002
103. Kako Y, M Massé, LS Huang, AR Tall, and **IJ Goldberg** Lipoprotein lipase deficiency and CETP in streptozotocin treated apoB-expressing mice. *J Lipid R*. 43:872-877, 2002
104. Mullick AE, RJ Deckelbaum, **IJ Goldberg**, M Al-Haideri, and JC Rutledge. Apolipoprotein E and Lipoprotein Lipase Increase Triglyceride-Rich Particle Binding but Decrease Particle Penetration in Arterial Wall. *Arterio Thromb Vasc Biol* . 22:2080-2085, 2002
105. Vogel S, R Piantedosi, SM O'Byrne, Kako, Y, L Quadro, **IJ Goldberg**, ME Gottesman, and WS Blaner. Retinol-binding protein-deficient mice: Biochemical basis for impaired vision. *Biochemistry*. 41:15360-15368, 2002.
106. Augustus AS, Y Kako, H Yagyu, and **IJ Goldberg**. Routes of fatty acid delivery to cardiac muscle: Modulation of lipoprotein lipolysis alters uptake of TG-derived fatty acids. *Am J Physiol Endocrinol Metab*, 284:E331-E339, 2003
107. Yagyu H, G Chen, M Yokoyama, K Hirata, A Augustus, Y Kako, T Seo, Y Hu, EP Lutz, M Merkel, A Bensdadoun, S Homma, and **IJ Goldberg**. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increased lipid uptake and produced a cardiomyopathy. *J Clin Invest* 111:419-426, 2003
108. Wasan KM, R Subramanian, M Kwong, **IJ Goldberg**, T Wright, and TP Johnson. Poloxamer407-mediated alterations in the activities of enzymes regulating lipid metabolism in rat. *J Pharm Pharmaceut Sci* 6:189-197, 2003
109. **Goldberg IJ**, A Isaacs, E Sehayek, JL Breslow, and L Huang Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice. *Athero*. 172:47-53, 2004
110. Lutz EP, Y Kako, H Yagyu, J Heeren, S Marks, T Wright, K Melford, O Ben-Zeev, H Radner, M Merkel, A Bensadoun, H Wong, and **IJ Goldberg** Mice expressing only covalent dimeric heparin-binding deficient lipoprotein lipase: Muscles inefficiently secrete dimeric enzyme. *J Biol Chem*. 279 238-244, 2004
111. Yokoyama M, H Yagyu, Y Hu, T Seo, K Hirata, S Homma, and **IJ Goldberg**. Apolipoprotein B production reduces lipotoxic cardiomyopathy: Studies in heart specific lipoprotein lipase transgenic mouse. *J Biol Chem*. 279: 4204-4211, 2004
112. Chen G, Wang D, H Yagyu, U Saxena, S Pillarisetti, and **IJ Goldberg**. Transcriptional regulation of heparanase by Inflammatory Cytokines, Oxidized LDL and fatty acids: Evidence for a Role in the Pathogenesis of Atherosclerosis. *Biochemistry*, 43:4971-4877, 2004
113. Augustus A, H Yagyu, G Haemmerle, A Bensadoun, R Vikramadithyan, S-Y Park, JK Kim, R Zechner, and **IJ Goldberg**. Cardiac-specific knockout of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression. *J Biol Chem*. 279:25050-7, 2004
114. Vikramadithyan RK, Y Kako, G Chen, Y Hu, E Arikawa-Hirasawa, Y Yamada, and **IJ Goldberg**. Atherosclerosis in perlecan heterozygous mice. *J Lipid Res*. 45:1806-12, 2004
115. Loike JD, DY Shabtai, R Neuhut, S Malitzky, E Lu, J Husemann, **IJ Goldberg**, and SC Silverstein Statins inhibit Fc- receptor mediated phagocytosis by macrophages: a process modulated by cell activation and cholesterol. *Arterio Thromb Vasc Biol*, 24:2051-6, 2004



116. Pillutla P, YC Hwang, T Wright, A Augustus, M Yokoyama, TP Johnston, R Ramasamy, **IJ Goldberg**. Perfusion of hearts with artificial lipid emulsions reproduces the metabolic abnormalities in lipotoxic cardiomyopathy. *Am J Physiol Endocrinol Metab.* 288:E1229-35, 2005
117. Pappan KL, Z Pan, G Kwon, CA Marshall, T Coleman, **IJ Goldberg**, ML McDaniel, CF Semenkovich. Pancreatic beta-cell lipoprotein lipase independently regulates islet glucose metabolism and normal insulin secretion. *J Biol Chem.* 280:9023-9, 2005
118. Vikramadithyan RK, K Hirata, H Yagyu, A Augustus, Y Hu, S Homma, **IJ Goldberg**. Peroxisome Proliferator Activated Receptor Agonists Modulate Heart Function in Transgenic Mice with Lipotoxic Cardiomyopathy. *J Pharmacol Exp Ther.* 313:586-93, 2005
119. Vikramadithyan RK, Y Hu, H-L Noh, C_P Liang, K Hallam, AR Tall, R Ramasamy, **IJ Goldberg**. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. *J Clin Invest.* 115 2434-2443, 2005
120. O'Byrne SM, N Wong, JM Libien, S Vogel, **IJ Goldberg**, W Baehr, K Palczewski, WS Blaner. Retinoid absorption and storage is impaired in mice lacking lecithin:retinal acyltransferase (LRAT). *J Biol Chem.* 280:35647-57, 2005
121. Augustus AS, J Buchanan, T-S Park, K Hirata, H Noh, J Sun, S Homma, J D'armiento, E D Abel, **IJ Goldberg**. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction, *J Biol Chem.* 281:8716-8723, 2006
122. Vines A, S Cahoon, **I Goldberg**, U Saxena U, S Pillarisetti. Novel inflammatory role for glycogen synthase-3 β in the inhibition of TNF- α and IL-1 β induced inflammatory gene expression. *J. Biol Chem.* 281(25):16985-16990, 2006
123. Park S-Y, Y-R Cho, H-J Kim, E-G Hong, T Higashimori, S J Lee, **IJ Goldberg**, GI Shulman, SM Najar, JK Kim. Glucose intolerance in mice with dominant-negative mutation of CEACAM1. *A J Physio Endo/Metab* 291(3):E517-24, 2006
124. Noh H-L, K Okajima, JD Molkentin, S Homma, **IJ Goldberg**, Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction. *AJ Physio, Endo/Metab.* 291:E755-60, 2006
125. Johnston TP, **IJ Goldberg**, Inhibition of pancreatic lipase by poloxamer 407 may provide an adjunct treatment strategy for weight loss. *J Pharmacy Pharmacology.* 58:1099-105 2006
126. Wu L, R Vikramadithyan, S Yu, C Pau, Y Hu, **IJ Goldberg**, HM Dansky. Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: Effects on plasma insulin, lipoproteins and atherosclerosis. *J Lipid Res.* 47:2215-22, 2006
127. Yokoyama M, T Seo, T-S Park, H Yagyu, Y Hu, N-H Son, AS Augustus, RK Vikramadithyan, R Ramakrishnan, LK Pulawa, R H. Eckel, **IJ Goldberg**. Cholesterol uptake into heart and skeletal muscle of lipoprotein lipase transgenic mice: Evidence that statin therapy increases muscle lipid uptake. *J Lipid Res.* 48:646-55, 2007
128. Son N-H, K Okajima, H Yamashita, M Yokoyama, LA Huggins, S Homma, MJ Szabolcs, L-S Huang, **IJ Goldberg**. Cardiomyocyte expression of PPAR γ leads to cardiac dysfunction. *J Clin Invest.* 117:2791-801, 2007
129. Lee, J, **IJ Goldberg**. Hypertriglyceridemia-induced pancreatitis created by oral estrogen and *in vitro* fertilization ovulation induction. *J Clin Lipid.* 2: 63-66, 2008
130. Takahashi M, M Yokoyama, Y Hiyama, Y Hu, K Melford, A Bensadoun, **IJ Goldberg**. In vivo arterial lipoprotein lipase expression augments inflammatory responses and impairs vascular dilatation. *ATVB* 28:455-462, 2008
131. **Goldberg IJ**, Y Hu, HL Noh, J Wei, LA Huggins, MG. Rackmill, H Hamai, BN Reid, WS Blaner L-S Huang. Decreased lipoprotein clearance is responsible for increased cholesterol in streptozotocin treated LDL receptor knockout mice, *Diabetes*, 57:1674-82, 2008



- 132 Reid BN, GP Ables, OA Otlivanchik, G Schoiswohl, R Zechner, WS Blaner, **IJ Goldberg**, RF Schwabe, SC Chua, Jr., L-S Huang. Hepatic Overexpression of Hormone-sensitive Lipase and Adipose Triglyceride Lipase Promotes Fatty Acid Oxidation, Stimulates Direct Release of Free Fatty Acids and Ameliorates Steatosis. *J Biol Chem*, 57:1674-82, 2008
133. Wongsiriroj N, R Piantedosi, K Palczewski, **IJ Goldberg**, TP Johnson, E. Li, WS Blaner. The molecular basis of retinoid absorption: a genetic dissection. *J Biol Chem* 83:3510-9, 2008.
134. Park T-S, Y Hu, H-L Noh, K Drosatos, K Okajima, J Buchanan, J Tuinei, S Homma, X-C Jiang, ED Abel, **Ira J. Goldberg**. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy/ *J Lipid Res*, 49:2101-12, 2008
135. Mzhavia N, S Yu, S Ikeda, TT Chu, **IJ Goldberg**, HM Dansky. Neuronatin: a new inflammation gene expressed on the aortic endothelium of diabetic mice. *Diabetes*, accepted, 2008
136. Yamashita H, KG. Bharadwaj, S Ikeda, T-S Park, **IJ Goldberg**. Cardiac Metabolic Compensation to Hypertension Requires Lipoprotein Lipase. *A J Physio, Endo/Metab* 295 E705-E713, 2008
137. Terasaka N, S Yu, L Yvan-Charvet, N Wang, N Mzhavia, R Langlois, T Pagler, R Li, CL Welch, **IJ Goldberg**, AR. Tall. ABCG1 and HDL protect against endothelial dysfunction induced by a high-cholesterol diet. *J Clin Invest* 118:3701-13, 2008
138. Noh H-L, Y Hu, T-S Park, T DiCioccio, AJ Nichols, K Okajima, S Homma, **IJ Goldberg**. Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. *J Pharmacol Exp Ther*, accepted
139. H Wang H, LA Knaub, D R Jensen, DY Jung, E-G Hong, AM. Coates, **IJ Goldberg**, B De la Houssaye, R Janssen, M Rahman, CS Choi, GI Shulman, JK. Kim, JE Friedman, RH. Eckel. Skeletal Muscle-Specific Deletion of Lipoprotein Lipase Enhances Insulin Signaling in Skeletal Muscle but Causes Insulin Resistance in Liver and White Adipose Tissue, *Diabetes*, accepted

Reviews, chapters and editorials

1. **Goldberg IJ**, NA Le, JR Paterniti, HN Ginsberg, FT Lindgren and WV Brown. The role of hepatic triglyceride lipase in primates. In: Atherosclerosis VI. ed. G. Schettler. Springer-Verlag, New York. 623-627, 1983.
2. Brown WV, **IJ Goldberg**, and HN Ginsberg. Treatment of common lipoprotein disorders. *Progress in cardiovascular disease*. 27:1-20, 1984.
3. Gibson JC, JR Paterniti, Jr. and **IJ Goldberg**. Measurements of heparin-releasable triacylglycerol lipases. In: *Lipid Research Methodology*, ed. T. Storey. Alan R. Liss, New York, 241-286, 1984.
4. Ginsberg HN, WV Brown and **IJ Goldberg**. Treatment of common lipoprotein disorders. *Primary Cardiology* 11:152-166, 1985.
5. Ginsberg HN, WV Brown and **IJ Goldberg**. Treatment of common lipoprotein disorders *Physicians Assistant* 10:122-142, 1986
6. **Goldberg IJ** and Ginsberg HN. Pathophysiology and treatment of disorders of lipoprotein metabolism in diabetes mellitus. In: *Principals of Diabetes Management*, ed., M. Bergman. Medical Examination Publishing Company, New York, 159-173, 1987.
7. Ginsberg HN and **IJ Goldberg**. Dyslipoproteinemias in thyroid disease. in *Clinical Biochemistry*. ed. JC Furchart and J Shepherd., Walter de Gruyter. Berlin, New York. 1989 pg 231-244.
8. **Goldberg IJ**. Summary and Comment - Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. *Diabetes Spectrum* 2:381, 1989.



9. Ginsberg HN, Y Arad and **IJ Goldberg**. Pathophysiology and Therapy of Hyperlipidemia *in* Cardiovascular Pharmacology (3rd Addition). ed. J. Antonnaccio, Raven Press, pg 485-514, 1990.
10. **Goldberg IJ**. Women and Diabetes: Maximizing for heart health. Diabetes Self-Management. November\December, pg 11-12, 1990.
11. **Goldberg IJ**, P Zukerberg, L Clark, D Gemson, W Karmally, and S Shea. Clinical management of high blood cholesterol and other lipid disorders: A case-oriented teaching program for the practicing physician. Published and distributed by the American Heart Association, New York City Affiliate, 1991.
12. **Goldberg IJ**. Lipoprotein metabolism in normal and uremic patients. American J. Kidney Dis. 21:87-90, 1993.
13. Horowitz BS, **IJ Goldberg**, J Merab, T Vanni, R Ramakrishnan and HN Ginsberg. Role of the kidney in increased clearance of apolipoprotein A-I in subjects with reduced high density lipoprotein cholesterol concentrations. *in* High density lipoproteins and atherosclerosis III. editors. NE Miller and AR Tall. Elsevier Science Publishers BN, pp. 215-222, 1992.
14. Ginsberg HN, JL Dixon and **IJ Goldberg**. The VLDL cascade system. The assembly, secretion, and intravascular metabolism of apoprotein B containing lipoproteins. *in* Lipoproteins in Health and Diseases. Editors Bretteridge JD, DR Illingsworth, and J Shephard., Arnold, p55-70, 1999.
15. Saxena U, and **IJ Goldberg**. Endothelial cells and atherosclerosis:lipoprotein metabolism, matrix interactions, and monocyte recruitment *in* Current Opinion in Lipidology. 5:316-322, 1994.
16. **Goldberg IJ**. in Medical Knowledge Self-Assessment Program (MKSAP) X – Endocrinology & Metabolism Section, Lipoprotein Disorders. *Editor*. L. Landsberg, American College of Physicians, Philadelphia, PA pages 1075-1079, 1995.
Questions and answers: Endocrine section - lipoproteins disorders included in 1253-1285.
17. **Goldberg, IJ** and HN Ginsberg. Diabetes and vascular disease risk. *Section Editor* W.V.Brown *in* Atlas of Heart Disease. *Series Editor*. E. Braunwald. volume 10:11.1-11.13, Current Medicine. Philadelphia, PA 1996.
18. **Goldberg IJ**, P Sivaram, SY Choi, N Parthasarathy, and WD Wagner. Lipoprotein lipase binding to endothelial cells: Specific protein-protein and protein glycosaminoglycan interactions. Atherosclerosis X. *Editors* FP Woodford, J Davignon, and A. Sniderman. Elsevier. Amsterdam. pages 1075-1079, 1995.
19. **Goldberg IJ**, AM Kaufman, VA Lavaria, T Vanni-Reyes, and NW Levin. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end stage renal disease. *Nephrol Dialysis & Transplantation* 11 Suppl 2:104-107, 1996.
20. **Goldberg IJ**. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherosclerosis. *J Lipid Res* 37:693-707, 1996.
21. **Goldberg IJ**. Lipid metabolism, update. *Curr. Op. Lipidol.* 7:U184-U186, 1996.
22. Ginsberg H.N. and **IJ Goldberg**. Disorders of Lipoprotein Metabolism. *in* Harrison's Principles of Internal Medicine, 14th edition, *Editors* Fauci AS, E Braunwald, KJ Isselbacher, JD Wilson, JB Martin, DL Kasper, SL Hauser and DL Longo. pp 2138-2149, 1997.
23. Ginsberg HN and **IJ Goldberg**. The pancreas and lipoprotein metabolism. *Handbook of Physiology*. volume II-7, pp 675-706, 2001.
24. **Goldberg IJ**, Ginsberg, HN, and Kunkes SH. Treatment of lipid disorders for the prevention and treatment of cardiovascular disease. Prepared for Oxford Health Plans, 1997.
25. **Goldberg IJ**, S Pillarisetti, WS Blaner, WD Wagner and JC Rutledge. Lipoprotein



- association with cells and matrix: modulation by lipase and proteoglycans. Atherosclerosis XI. Editors Jacotot B, D. Mathe, J-C Fuchart. Elsevier, Amsterdam pp 887-894, 1998.
- 26. **Goldberg IJ** and CH Tuck. Endothelial lipases in disease. *in* Plasma lipids and their role in disease, editors P Barter and K-A Rye. Harwood Academic Publishers pp 203-216, 1999.
 - 27. **Goldberg IJ**. Lipoproteins *in* McGraw-Hill Encyclopedia of Science and Technology, Biochemistry ed. A. Spector.
 - 28. **Goldberg IJ**. Commentary on: Do physicians follow the NCEP guidelines? Cardiology Review, 16:16, 1999.
 - 29. Rutledge JC, **IJ Goldberg**, and AE Mullick. Hypertriglyceridemia: consequences for atherosclerosis. Preventive Cardiology 81-86, 1999
 - 30. **Goldberg IJ**, Y Kako, EP Lutz. Responses to eating: lipoproteins, lipolytic products and atherosclerosis. Current Opinion in Lipidology 11:234-241, 2000.
 - 31. **Goldberg IJ**. Commentary on: High-density lipoprotein as an indicator of CAD. Cardiology Review, 17:31, 2000.
 - 32. Krauss RM et al. AHA Dietary Guidelines –Revision 2000. Circulation 102:2284-2299, 2000.
 - 33. Ginsberg H.N. and **I.J. Goldberg**. Disorders of Lipoprotein Metabolism. *in* Harrison's Principles of Internal Medicine, 15th edition, Editors Fauci AS, E Braunwald, KJ Isselbacher, L Jameson, JB Martin, DL Kasper, SL Hauser and DL Longo. Chapter 344, pages 2245-2256 2001.
 - 34. **Goldberg I.J.**, L Mosca, MR Piano, EA Fisher. AHA Science Advisory, Wine and your heart. Circ 103:472-475, 2001.
 - 35. Ginsberg HN, **IJ Goldberg**, C Tuck. Endocrine effects on lipids, chapter 165 in Principles and Practice of Endocrinology and Metabolism, ed. KL Becker. Lippincott Williams and Wilkins. Philadelphia. Silverchair Science and Communications, Inc, Chalottesville, VA pages 1538-1543, 2001.
 - 36. **Goldberg IJ**. Diabetes dyslipidemia: causes and consequences. J Clin Endo Metab. 86:965-71, 2001.
 - 37. **Goldberg IJ**, M Merkel. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci. 1;6:D388-405, 2001.
 - 38. **Goldberg IJ**, Zukerberg P. Disorders of lipoprotein metabolism *in* Difficult cases in endocrinology. Ed. M. Molitch. Humana Press 2002.
 - 39. **Goldberg IJ**. Hyperlipidemia: pathogenesis and management in diabetes mellitus. Chapter 11 *in* Principles of Diabetes Mellitus. ed. L Poretsky. Kluwer. Boston, 459-472. 2002
 - 40. **Goldberg IJ**. Can modifying other lipid factors reduce cardiac events. Cardiology Review 18:15-15, 2001
 - 41. Rossetti L and **IJ Goldberg**. A new piece in the diabetes puzzle. Nature Medicine 8:112-114, 2002
 - 42. Merkel M, RH Eckel, **IJ Goldberg**. Lipoprotein lipase: genetics, lipid uptake and regulation. J. Lipid Res. 43: 1997-2006, 2002
 - 43. **Goldberg I.J.** To drink or not to drink? N Eng J Med. 348:163-164, 2003
 - 44. **Goldberg IJ**. Assessing CHD risk: What are we missing? Cardio Rev 21:48-49, 2004
 - 45. Otard JK and **IJ Goldberg**. Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Current atherosclerosis reports. 6:335-42, 2004.
 - 46. **Goldberg IJ**. Why does diabetes increase atherosclerosis? I don't know. J Clin Invest, 114:613-5, 2004.
 - 47. Kahlil M, WD Wagner, and **IJ Goldberg**. Arterial lipoprotein retention and the biochemistry of atherosclerosis initiation. Arterio Thromb Vasc Biol, 24:2211-8, 2004.



48. Karmally W, and **IJ Goldberg**. Commentary on OmniHeart Trial. Nature Clinical Practice Cardiovascular Medicine, 2006.
49. **Goldberg IJ** and HN Ginsberg. Ins and outs modulating hepatic triglyceride and development of non-alcoholic fatty liver disease. Gastro. 130:1343-1346, 2006
50. **Goldberg IJ**, HM Dansky. Diabetic vascular disease, an experimental objective. Arterio Thromb Vasc Biol, 26:1693-701, 2006
51. Noh H-L, H Yamashita, **IJ Goldberg**. Cardiac metabolism and mechanics are altered by genetic loss of lipoprotein triglyceride lipolysis. Cardiovasc Drugs Ther. 20:441-4. 2006.
52. Park, T-S, H Yamashita, WS Blaner, **IJ Goldberg**. Lipids in the heart, a source of fuel and a source of toxins. Current Opinion in Lipidology, 18:277-82. 2007
53. Hsueh W, ED Abel, JL Breslow, N Maeda, RC Davis, EA Fisher, H Dansky, DA McClain, R McIndoe, MK Wasif, C Rabadán-Diehl, **IJ Goldberg**, Recipes for Creating Animal Models of Diabetic Cardiovascular Disease, Circ Res. 100:1415-27.2007
54. Labossiere R and **IJ Goldberg**, Management of Hypertriglyceridemia. in Therapeutic Lipidology, ed. MH Davidson, PP Toth, KC Maki Humana Press, page 201-220, 07 (in press)
55. Dansky, HM, **IJ Goldberg**. Effects of diabetes on murine lipoproteins and vascular disease. Curr Drug Targets 8:1196-202, 2007
56. Lee J, **IJ Goldberg**. Lipoprotein lipase-derived fatty acids: Physiology and dysfunction Current Hypertension reports. 9: 462-466, 2008.
57. Wilson PWF, HR Black, A Fabricatore, **IJ Goldberg**. Challenges to the diagnosis, evaluation, treatment and management of clustered cardiometabolic risk factors. Journal of the CardioMetabolic Syndrome, 08
58. **Goldberg IJ**, RH Eckel, NA Abumrad. Regulation of fatty acid uptake into tissues: J Lipid Res. accepted

Published Abstracts (over 100)



Abstracts

1. Davis, T.F., Platzer, M., Goldberg, I.J. Gonadotropin-induced regulation of lipoprotein and prolactin receptor in the rat testes. *Endo. Soc.* 63rd Meeting, p. 788, 1981
2. Goldberg, I.J., Le, N.A., Paterniti, J.R., Jr., Ginsberg, H.N., Brown, W.V. Effect of inhibition of hepatic triglyceride lipase on very low density lipoprotein apoprotein B catabolism in macaca fascicularis. *Clin. Res.* 29:539A, 1981
3. Goldberg, I.G., Le, N.A., Paterniti, J.R., Brown, W.V. Evidence for the metabolic heterogeneity of low density lipoproteins. *Clin. Res.* 31:186a, 1983.
4. Goldberg, I.J., Paterniti, J.R., France, D.S., Martinelli, G., Cornicelli, J.A. An enzyme - linked immunosorbent assay for human lipoprotein lipase. *Arterio.* 4:551a, 1984.
5. Ginsberg, H., Goldberg, I., Wang-Iverson, P., Gitler, E., Le, N.A., Gilbert, H., Brown, W.V. Increased non-receptor mediated low density lipoprotein catabolism in subjects with myeloproliferative diseases. *Clin. Res.* 30:524a, 1985.
6. Le, N.A., Goldberg, I.J., Ginsberg, H.N., Brown, W.V. Direct production of low density lipoprotein in the monkey. Comparison of endogenous versus exogenous tracers. *Arterio.* 3:503, 1983.
7. Paterniti, J.R. Jr., France, D.S., Martinelli, G. Goldberg, I.J., Gerber, M., Brown, W.V. Immunochemical localization of human hepatic triglyceride lipase using a monoclonal antibody. *Arterio.* 4:533, 1984.
8. Goldberg, I.J., Nilaver, G., MacIntosh, A.M., Paterniti, J.R., Blum, C.B., Zimmerman, E.A. Localization of lipoprotein lipase in monkey hypothalamus and pituitary. *Arterio.* 4:533, 1984.
9. Koritnik, D.R., Goldberg, I.J., Rudel, L.L. Contraceptive steroids effects on hepatic lipase and lipoprotein lipase activity in macques. *Fed. Proc.* 44:1454, 1985.
10. Kandel, J.J., Goldberg, I.J. The association of the heparin-releasable lipases with plasma lipoproteins in normal and hypertriglyceridemic humans. *Clin. Res.* 33:433a, 1985.
11. Goldberg, I.J., Kandel, J.J., Blum, C.B., Ginsberg, H.N. Association of human lipoprotein lipase and hepatic triglyceride lipase with plasma lipoproteins. *Arterio* 5:551a, 1985
12. Handley, D.A., Paterniti, J.R., Cornicelli, J.A., Goldberg, I.J. Membrane localization of lipoprotein lipase on human monocyte macrophages by the immunocolloidal gold technique. *Arterio.* 5:509a, 1985.
13. Miller, S., Bush, T., Levine, H., Goldberg, I.J. Parameters of care offered in New York City area diabetes clinics. *Diabetes* 35:594 - Supp. 1, 1986.
14. Goldberg, I.J., Ginsberg, H.N., Le, N.A., Krauss, R.M., Lindgren, F.T. VLDL catabolism in the lipoprotein lipase-deficient monkey: Evidence for an essential role of LPL in LDL production. *Arterio* 6:566a, 1986.
15. Blaner, W.S., Moukides, M., Goldberg, I.J., Piantedosi, R., Mertz, J. Substrate specificities of human bile activated lipase, rat liver retinyl palmitate hydrolase, and bovine retinal epithelium homogenates for retinyl esters. *Fed. Proc.* 46:2070, 1987.
16. Saxena, U., Goldberg, I.J., Witte, L.D. Endothelial cell lipoprotein lipase is regulated by plasma lipoproteins and free fatty acids. *Arterio.* 7:538a, 1987.
17. Cholst, I.N., Bush, T., Ginsberg, H.N., and Goldberg, I.J. Effect of transdermal estrogen replacement on lipids and apoproteins. *Int. Obs. & Gyn. Society* 1988.
18. Traber, M.G., Goldberg, I.J., Davidson, E., and Kayden, H.J. Lipid uptake by Caco-2 cells during hydrolysis of triglyceride emulsions by bile activated lipase. *Int. Athero. Society*, 1988.
19. Goldberg, I.J., Soprano, D.R., Wyatt, M.L., Vanni, T.M., Kirchgessner and Schotz, M.C. Sites of lipoprotein lipase synthesis: In situ hybridization studies of mRNA. *Arterio.* 8:595a, 1988.
20. Saxena, U., Kern, P.A., Goldberg, I.J. Mechanism for the regulation of circulating and



- endothelial cell (EC) bound lipoprotein lipase (LPL) by free fatty acids (FFA). Arterio. 8:561a, 1988.
21. Goldberg, I.J., Holleran, S., Ramakrishnan, R., Palmer, R.H., Dell, R.B. and Goodman, D.S. Effect of long-term treatment with lovastatin on the parameters of whole body cholesterol metabolism. Arterio. 8:588a, 1988.
 22. Scherardi, C.A., Bisgaier, C.L., Ginsberg, H.N., and Goldberg, I.J. Modulator role of apolipoprotein A-IV in the activation of lipoprotein lipase. Arterio. 8:595a, 1988.
 23. Ginsberg, H.N., Ngai, N., Lee, J. Goldberg, I. Immunoaffinity isolation of E-deficient subclasses of very low density lipoproteins. Arterio. 8:599a, 1988.
 24. Gemson, D.H., I.J. Goldberg, R.P. Sloan, and P. Messeri. Cholesterol screening at the worksite: Impact of Nurse Counseling on diet and cardiovascular risk factors. Circulation. 80:59, 1989.
 25. Saxena, U. L.D. Witte, and I.J. Goldberg. Tumor necrosis factors induces the release of endothelial cell bound lipoprotein lipase. Arterio. 9:695a, 1989.
 26. Goldberg, I.J., Blaner, W.S., Vanni, T.M., Moukides, M., Ramakrishnan, R. Lipoprotein lipase (LPL) regulation of high density lipoprotein (HDL) catabolism. Arterio. 9:695a, 1989.
 27. Karmally, W., I.J. Goldberg, and H. Ginsberg. Normalization of plasma triglyceride and high density lipoprotein cholesterol by omega-3-fatty acid supplementation of a low fat diet in a patient with lipoprotein lipase deficiency. Arterio. 9:709a, 1989
 28. Fried, S.K., I. Turkenkopf, I.J. Goldberg, M. Doolittle, O. Ben-Zeev, M.C. Schotz, and M.R.C. Greenwood. Lipoprotein lipase synthesis and degradation in adipocytes from lean and obese Zucker rats. FASEB J. 4:3775, 1990.
 29. Yacoub, L.K., T.M. Vanni, and I.J. Goldberg. Lipoprotein lipase mRNA in neonatal and adult mouse tissues: comparison of normal and combined lipase deficient (cld) mice assessed by in situ hybridization. Clin. Res. 38:396, 1990.
 30. Saxena, U., M.G. Klein, and I.J. Goldberg. Transport of lipoprotein lipase across endothelial cell monolayers. Arteriosclerosis 10:850a, 1990.
 31. Seres, D.S., G.W. Strein, S. Hashim, I. Goldberg, and N.W. Levin. Plasma triglyceride metabolism is enhanced by elevation of lipase activity as a result of high flux hemodialysis in patients with end-stage renal disease. Clin. Res. 30:655a 1991.
 32. Kleinherenbrink-Stins, M.F., F.R. Maxfield, and I.J. Goldberg. Visualization of lipoprotein lipase transport across endothelial cell monolayers. Arteriosclerosis & Thromb. 11: 1412a, 1991.
 33. Sasaki, A., and I.J. Goldberg. Release of lipoprotein lipase from cultured adipocytes. Arteriosclerosis & Thromb. 11: 1503a, 1991.
 34. Goldberg, I.J., J.P. Merab, B. Horowitz, W.S. Blaner, T.M. Vanni, and H.N. Gisberg. In vitro lipolysis of triglyceride enriched high density lipoproteins leads to increased uptake of apoA-I by the isolated perfused kidney. Arteriosclerosis & Thromb. 11: 1502a, 1991.
 35. Saxena, U., M.G. Klein, and I.J. Goldberg. Lipoprotein lipase increases lipoprotein retention by subendothelial cell matrix. Arteriosclerosis & Thromb. 11: 1412a, 1991.
 36. Horowitz, B.S., I.J. Goldberg, J. Merab, T. Vanni, R. Ramakrishnan, and H.N. Ginsberg. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. Arteriosclerosis & Thromb. 1408a, 1991.
 37. Yla-Herttuala, S., B.A. Lipton, M.E. Rosenfeld, I. Goldberg, D. Steinberg, and J.L. Witztum. Arterial macrophages express lipoprotein lipase mRNA and protein in atherosclerotic plaques. Arteriosclerosis & Thromb. 11: 1407a, 1991.
 38. Ishimura-Oka, K., F. Faustinella, N. Schacter, L.C. Smith, W.A. Hide, K. Oka, C.F. Semenkovich, I.J. Goldberg, P.D. Thompson, T. Coleman, W.V. Brown, and L. Chan. A common missense (Asp²⁵⁰-Asn) mutation in the lipoprotein lipase gene in two



- unrelated families with familial lipoprotein lipase deficiency. 11: 1415a, 1991.
39. Sivaram, P., M.G. Klein, A. Sasaki, M.F. Stins and I.J. Goldberg. Identification of a heparin releasable lipoprotein lipase binding protein. Circulation 86: supplement I, I-156.
40. Rumsey S., J.C. Obunike, Y. Arad, R. Deckelbaum, and I.J. Goldberg. Lipoprotein lipase mediated uptake and degradation of low density lipoproteins by fibroblasts and macrophages. Circulation 86: supplement I, I-155.
41. Rutledge, J.C. and I.J. Goldberg. Effect of lipoprotein lipase on LDL vascular wall efflux. Arteriosclerosis Council Abstracts, page 83, 1992.
42. Sasaki, I., P. Sivaram, and I.J. Goldberg. Adipocytes synthesize a 116 kDa lipoprotein lipase binding protein. Clin. Res. 41:391A, 1993.
43. Obunike, J.C., I.J. Edwards, D.K. Strickland, L.K. Curtiss, R.J. Deckelbaum, and I.J. Goldberg. Evidence for two separate mechanisms for lipoprotein lipase mediated uptake of low density lipoproteins. Circ. 88:I-320, 1993.
44. Blaner, W.S., J.C. Obunike, M. Al-Haideri, A. Sasaki, R.J. Deckelbaum, and I.J. Goldberg. Lipooprotein lipase hydrolyses retinyl ester and increases retinoid uptake by cells. Circ. 88:I-179, 1993.
45. Al-Hadairi, M., E. Granot, B. Schweigelsohn, T. Vogel, M. Gorecki, I.J. Goldberg, and R.J. Deckelbaum. Apoprotein E stimulates non-receptor triglyceride-rich particle cellular uptake. Circ. 88:I-321, 1993.
46. Edwards, I.J., H. Xu, I.J. Goldberg, and W.D. Wagner. Cell surface proteoglycans which bind lipoprotein lipase are upregulated in differentiated macrophages. Circ. 88:I-365, 1993.
47. Parthasarathy, N, J. Wright, P. Sivaram, I.J. Goldberg, and W.D. Wagner. Identification of specific endothelial cell heparan sulfate oligosaccharides which bind to lipoprotein lipase Circ. 88:I-365, 1993.
48. Rouis, M., L. Previato, I. Goldberg, H. Ginsberg, J.D. Brunzell, H.B. Brewer, jr., and S. Santamarino-Fojo. Unique therapeutic response to medium chain triglyceride and omega-3-fatty acid in two patients with familial chylomicronemia. Circ. 88:I-76, 1993.
49. Choi, S.Y., P. Sivaram, D.E. Walker, L.K. Curtiss and I.J. Goldberg. Lipoprotein lipase binds to the amino terminal region of apolipoprotein B. Clin. Res. 42:198A 1994
50. Choi S.Y., P. Sivaram. D. Walker, L.K. Curtiss and I.J. Goldberg. The amino terminal region of apolipoprotein B binds to lipoprotein lipase. 90:I-405, 1994.
51. Sivaram, P. A. Sasaki, T. V. Reyes, and I.J. Goldberg. Endothelial cell conditioned medium releases lipoprotein lipase from adipocytes and stabilizes its activity. Circ. 90:I-405, 1994.
52. Agnani, G., B. Le Roy, C.J. Mann, F. Paillard, I.J. Goldberg, B.E. Bihain, and F.T. Yen. Defective binding of hypertriglyceridemic VLDL to heparan sulfate proteoglycans delays TG hydrolysis. Circ. 90:I-489, 1994.
53. Zhong, S., I.J. Goldberg, C. Bruce, E. Rubin, J. Breslow, and A. Tall. Human apoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. Circ. 90:I-81, 1994.
54. Pang L, P Sivaram and I J Goldberg. Cell expression of an amino terminal fragment of apolipoprotein B increases lipoprotein lipase binding to cells. Arteriosclerosis abstract 104. 1995.
55. Goldberg IJ, T M Vanni, P Sivaram. Endothelial cells produce an amino-terminal fragment of apolipoprotein B. Circ. 92:I-164, 1995
56. Choi S Y , M C Komaromy, I J Goldberg and A D Cooper. Interaction between apoB and hepatic lipase may mediate enhanced lipoprotein uptake by LDL receptor. Arteriosclerosis abstract 100. 1995.



57. P.Sivaram and I J Goldberg. Lysolecithin induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix.Circ. 92:I-424, 1995
58. Obunike JC, P Sivaram, A Sasaki, I J Goldberg. Mechanisms of lipoprotein lipase degradation by adipocytes: LDL receptor related protein and proteoglycan mediated pathways. Circ. 92:I-3, 1995
59. Yin B, P H Weinstock, J L Breslow, J D Loike, and I J Goldberg. Macrophage lipoprotein lipase increases phagocytosis. Circ. 94:2320, 1996
60. Obunike, J C, S Pillarisetti, S Paka, A Sasaki, and I J Goldberg. Lipoprotein lipase can function as a monocyte adhesion protein. Circ. 94:2300, 1996
61. Rutledge JC, M W Woo, A A Rezai, L K Curtiss, and I J Goldberg. Two mechanisms whereby lipoprotein lipase increases LDL accumulation in the artery wall. Atherosclerosis Council Abstracts, 1996,
62. Pillarisetti S, S Paka, J C Obunike, L Berglund, and I J Goldberg. Reduced heparan sulfate promotes lipoprotein(a) retention by sunendothelial matrix.Circ. 94:2298, 1996
63. Masucci-Margoulas, I Goldberg, C Bisgaier, J L Breslow, and A R Tall. A murine model of familial combinedhyperlipoproteinemia Circ. 94:3696, 1996
64. Lobritto S J, S L Sturley, Gretch D F, Pang L, Wang L, Goldberg I J, Al-Haideri M, Galeano N F, Attie A, and Deckelbaum R J. Truncated apoprotein B peptides bind to model lipoprotein particles and modulate interactiions with cultured cells.Circ. 94:0600, 1996
65. Choi, S.Y., P.H. Weinstock, L.K. Curtiss, and A.D. Cooper. An hepatic lipase-apoB interaction accelerates lipoprotein uptake. Circ. 94:2318, 1996
66. Gardner G, Woo M, Goldberg I and Rutledge JC. Increased lipolysis of triglyceride-rich lipoproteins enhances artery wall permeability and lipoprotein retention. J Am Col C 29:6464, 1997
67. Balagopalakrishna C, S Pillarisetti, and I J Goldberg. Lypolysis-induced iron relase form transferrin promotes lipoprotein oxidation. J. Inv. Med. 45:269A, 1997
68. Pillarisetti S, S Paka, J Obunike and I J Goldberg. Oxidized LDL and lysolecithin induced decrease in subendothelial heparan sulfate is due to the actions of an endothelial heparanase. Xth International Symposium on Atherosclerosis.
69. Merkel, M, P H Weinstock, B Yin, I.J Goldberg, and JL Breslow. Liver expression of lipoprotein lipase rescues LPL knockout mice with cachexia during suckling, but normal development on a chow diet. Circ. 96:608, 1997
70. Goldberg, IJ, L Paka, L Pang, JC Obunike and S Pillarisetti. Evidence that the amino-terminal region of apolipoprotein B is the atherogenic portion of low density lipoprotein. Circ. 96:206, 1997
71. Wagner WD, IJ Goldberg, N Parthasarathy, and JD Bottoms. Decorin but not biglycan binding to low density lipoprotein is enhanced by lipoprotein lipase. Circ. 96:208, 1997
72. Obunike JC, S Pillarisetti, L Paka, MJ Butteri, Y-Y Ho, WD Wagner, RJ Deckelbaum, and IJ Goldberg. Heparin binding proteins apolipoproteinE and lipoprotein lipase enhance production of proteoglycans. Circ. 96:302, 1997
73. Kako Y, L-S Huang, IJ Goldberg. Lipoprotein lipase does not correct hypercholesterolemia in streptozotocin diabetic male human apoB transgenic mice. Diabetes 47:A31, 1998
74. Seo T, M Al-Haideri, IJ Goldberg, RJ Deckelbaum. Selective uptake of LDL-cholesteryl esters is stimulated by lipoprotein lipase and oleic acid via a calcium independent pathway involving cell surface proteoglycans. Circ 98:I314.
75. Merkel M, Y Kako, H Radner, IS Cho, JD Brunzell, IJ Goldberg, JL Breslow. Transgenic mice expressing catalytically inactive LPL in muscle have increased muscle uptake of VLDL particles. Circ 98:I591
76. Kako Y, T Shin, IJ Goldberg. Quantitative assessment of atherosclerotic lesions with echocardiography in transgenic mice. Circ 98:I799

77. Kako Y, M Massé, L-S Huang, IJ Goldberg. Exacerbation of diabetes induced lipoprotein changes with lipoprotein lipase deficiency in human apoB transgenic mice. *Diabetes* 48: Suppl 1, A2, 1999
78. Kako Y, M Massé, AR Tall, IJ Goldberg. Cholesteryl ester transfer protein (CETP) transgene induces marked cholesteryl ester accumulation in VLDL and LDL in a combined hyperlipidemic model with low lipoprotein lipase (LpL) and expression of human apoB. *Circ* 100: I-403, 1999
79. Conde K, Y Kako, T Ebara, Y Xu, R. Ramakrishnan, IJ Goldberg, NS Shachter. Hyperlipidemia in streptozotocin diabetic mice is associated with selective impairment of apoB48-particle clearance related to increased C apolipoproteins and decreased liver heparan sulfate. *Circ* 100: I-329, 1999
80. Merkel M, Y Kako, K Melford, JL Breslow, A Bensadoun, IJ Goldberg. Transgenic mice expressing lipoprotein lipase (LpL) with a mutation in the carboxyl-terminal heparin binding region have large amounts of inactive LpL in preheparin plasma. *Circ* 100: I-403, 1999
81. Obunike JC, L Paka, T Kapotopodis, Z Li, DK Strickland, S Pillarisetti, IJ Goldberg. Lipoprotein lipase transcytosis across endothelial cells is mediated by a receptor associated protein (RAP)-sensitive mechanism. *Circ* 100: I-329, 1999.
82. Li Z, Y Kako, JH Yang, MW Freeman, JM Glick, IJ Goldberg. Effects of overexpression of apoB17 on endogenous apoB production in vitro and in vivo.
83. Mullick AE; Deckelbaum R; Goldberg IJ; Al-Haideri M; Rutledge JC. ApoE increases triglyceride-rich particle binding to the endothelial layer but decreases penetration into the artery wall. In: *Experimental Biology* 2000:327.4
84. Kim JA, W. Velez-Carrasco, Y Kako, J Fillmore, Y Chen p Perret, IJ Goldberg, JL Breslow, GI Shulman. Effect of muscle-specific overexpression of lipoprotein lipase (LPL) on insulin action and signaling in the awake mice. *ADA Diabetes* 49: I-54, 2000.
85. Kako Y, M Masse, AR Tall, IJ Goldberg. Creation of diabetic dyslipidemia in mice. *ADA Diabetes* 49: I-53, 2000.
86. Lutz EP, M Merkel , Y Kako, K Melford, H Radner , JL Breslow, A Bensadoun, IJ Goldberg. Mice expressing only mutated heparin-binding defective lipoprotein lipase (LpL) have increased postprandial free fatty acids and decreased tissue lipid uptake: direct evidence that the carboxyl terminal heparan sulfate binding region is essential for normal LpL physiologic functions. *Circ* 102: II- 204, 2000.
87. Merkel M, W Dudeck, F Rinninger, J Heeren, H Radner, R Zechner, IJ Goldberg, JL Breslow, H Greten Catalytically inactive lipoprotein lipase solely expressed in muscle mediates selective cholesterol ester uptake from chylomicrons. *Circ* 102: II- 205, 2000.
88. Kako Y, J Mason, G Xiao, R Pergolizzi, IJ Goldberg, I Goldberg, S Pillarisetti. Scatter Factor, which improves endothelial function, inhibits atherosclerosis in ApoE-Null mice despite increasing VLDL and LDL. *Circ* 102: II-890, 2000.
89. Obunike JC, Z Li, T Katopodis, KF Kozarsky, S Pillarisetti, IJ Goldberg. Lipoprotein lipase (LpL) transport across endothelial cell monolayers correlates with expression of the VLDL receptor. *Circ* 102: II-892, 2000
90. Kako Y, M Masse, AR Tall, LS Huang, IJ Goldberg. Streptozotocin (STZ) increases atherosclerosis, but only in mice expressing cholesteryl ester transfer protein (CETP). *Circ* 102: II-1124, 2000.
91. Hussain MM, JC Obunike, A Shaheen, MCP Hahnemann, MJ Hussain, GS Shulness, IJ Goldberg. High Affinity binding between lipoproteins and lipoprotein lipase involves multiple ionic and hydrophobic interactions, does not require enzyme activity, and is modulated by salt, detergents and glycosaminoglycans. *Circ* 102: II-1183, 2000.
92. Yagyu H, EP Lutz, Y Kako, S Marks, Y Hu, A Bensadoun, IJ Goldberg. VLDL receptor (VLDLR) deficiency leads to hypertriglyceridemia and abnormal



- regulation of lipoprotein lipase in lipoprotein lipase heterozygous knockout (LpL1) mice. Circ 104: II-1289, 2001
93. Lutz EP, Y Kako, S Marks, K Melford, A Bensadoun, IJ Goldberg. Covalent dimeric heparin-binding defective lipoprotein lipase has increased enzymatic stability and prevents neonatal demise of lipoprotein lipase knockout mice. Circ 104: II-1291. 2001
94. Wang D, G Chen, U Saxena, I Goldberg, S Pillarisetti . A secreted endothelial heparanase is induced by inflammatory cytokines and oxidized LDL. Evidence for a role in the pathogenesis of atherosclerosis. Circ 104: II-1315, 2001
95. Yagyu H, G Chen, Y Kako, A Augustus, T Seo, Y Hu, EP Lutz, M Merkel, A Bensadoun, IJ Goldberg. Cardiomyocyte Expression of non-transferable lipoprotein lipase (LPL): non-endothelial cell associated LPL is active and produces a cardiomyopathy. Circ 106: II-614, 2002
96. Augustus A, Y Kako, H Yagyu, IJ Goldberg. Routes of fatty acid delivery to cardiac muscle: Modulation of lipoprotein lipolysis alters uptake of free fatty acids. Circ 106: II-1321, 2002
97. Augustus A, Y Kako, H Yagyu, IJ Goldberg. Fatty acid delivery to cardiac muscle: Glucose/Insulin independent fuel. ADA Diabetes 51: II-2387, 2002
98. Vikramadithyan RK, M Yokoyama, H Yagyu, K Hirata, Y Hu, S Homma, IJ Goldberg. Lipotoxic Dilated Cardiomyopathy in Mice is Exacerbated By a PPAR α Agonist, But Not By a Dual Agonist of PPAR α and PPAR γ , presented AHA, 2003
99. Augustus A, H Yagyu, G Haemmerle, R Zechner, IJ Goldberg. Cardiac-specific Knockout of Lipoprotein Lipase Induces Hypertriglyceridemia and Altered Postprandial Lipid Metabolism, presented AHA 2003
100. Pappan, KL, Z-J Pan, G Kwon, CA Marshall, T Coleman, I J Goldberg, ML McDaniel, CF Semenkovich. Diabetes 53: Suppl 2, page A-76
101. Noh H-L, K Okajima, JD Molkentin, S Homma, J Goldberg. Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction. ATVB 2006.
102. Takahashi M, M Yokoyama, T Seo, A Bensadoun, IJ Goldberg. Endothelium specific overexpression of human Lipoprotein Lipase leads to fatty liver in mice/ ATVB 2006.
103. Son N-H, K Okajima, H Yamashita, S Homma, MJ Szabolcs, L-S Huang, IJ Goldberg. Cardiomyocyte expression of PPAR γ leads to cardiac dysfunction ADA Meeting 2006
104. Reid B, SC Chua, G Ables, IJ Goldberg, R Schwabe, L-S Huang. Adenoviral Overexpression of Hormone-Sensitive Lipase Reduces Hepatic Steatosis Without Increasing Triglyceride Secretion in Leptin-Deficient ob/ob Mice. ATVB 2007
105. N Mzhavia, S Yu, I Goldberg, HM Dansky. Neuronatin: a new inflammation gene expressed on the aortic endothelium of diabetic mice. ATVB 2007
106. Yamashita H, S Ikeda, T-S Park, I Goldberg. Cardiac lipoprotein lipase (LpL)-derived fatty acid (FA) is necessary to protect hearts under the stress induced by chronic angiotensin II (Ang II) treatment. ATVB 07
107. Noh H-L, Y Hu, AT DiCioccio, AJ Nichols, IJ Goldberg. Lidorestat, an inhibitor of aldose reductase (AR), improves mortality in diabetic human AR transgenic mice. ADA 07
108. Pulawa LK, DR Jensen, DY Jung, E-G Hong, AM Coates, JE. Friedman, IJ. Goldberg, JK. Kim, RH. Eckel. Muscle-Specific Lipoprotein Lipase Deletion Increases Insulin Action in Skeletal Muscle with Resultant Excess Adipose Tissue Deposition and Systemic Insulin Resistance, ADA 07
109. Chahil T, C Ngai, A Bensadoun, I Goldberg, S Holleran, R Ramakrishnan, H Ginsberg. Effects of Pioglitazone and Rosiglitazone on Lipid Metabolism, ADA 07
110. Yamashita, H, S Ikeda, T-S Park, KG Ba, IJ Goldberg. Deficiency of cardiac lipoprotein lipase prevents normal compensation to hypertensive stress. AHA 07
111. Park T-S, Y Hu, K Okajima, J Buchanan, S Homma, MM. Davidson, ED Abel, X-C Jiang, I J Goldberg. Inhibition of ceramide biosynthesis decreases cardiomyopathy in



Ira J. Goldberg, M.D.

lipoprotein lipase (LpL) lipotoxicity. AHA 07

112. Duncan JG, JL Fong, J Yang, N Sambandam, M Courtois, IJ Goldberg, DP Kelly. Cardiac Lipoprotein Lipase Deficiency Rescues Lipotoxic Cardiomyopathy and Identifies a Distinct Cellular PPAR α Signaling Pathway. AHA 07
113. Wong H, LA Knaub, IJ Goldberg, JK Kim, GI Shulman, JC Friedman, RH Eckel. Reducing lipid partitioning to skeletal muscle in skeletal muscle-specific lipoprotein lipase knockout mice increased muscle insulin action and causes insulin resistance in liver and adipose and ultimate obesity. ADA 08
114. Terasaka N, S Yu, LY Charvet, N Wang, N Mzhavia, IJ Goldberg, AR Tall. Roles of ABCG1 and HDL in Endothelial Function. ATVB 2008

